Investment analysts at StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Get Free Report) in a research report issued to clients and investors on Thursday. The brokerage set a “hold” rating on the stock.
Trinity Biotech Trading Up 3.6 %
NASDAQ TRIB opened at $0.83 on Thursday. The stock has a fifty day simple moving average of $0.89 and a 200-day simple moving average of $1.53. The stock has a market cap of $14.96 million, a PE ratio of -0.37 and a beta of 1.03. Trinity Biotech has a twelve month low of $0.74 and a twelve month high of $3.55.
Institutional Trading of Trinity Biotech
A hedge fund recently raised its stake in Trinity Biotech stock. Hunter Associates Investment Management LLC raised its position in shares of Trinity Biotech plc (NASDAQ:TRIB – Free Report) by 7.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 359,810 shares of the company’s stock after buying an additional 26,100 shares during the period. Hunter Associates Investment Management LLC owned about 4.72% of Trinity Biotech worth $390,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 78.97% of the company’s stock.
Trinity Biotech Company Profile
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Read More
- Five stocks we like better than Trinity Biotech
- How to Short a Stock in 5 Easy Steps
- IBM’s AI Bet Pays Off—What’s Next for Investors?
- Pros And Cons Of Monthly Dividend Stocks
- 3 Reasons to Treat AMD’s Drop as an Entry Opportunity
- What Are Dividend Champions? How to Invest in the Champions
- Qualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
